Sentiment · REGN
Lobbying Spend for REGN
AI-generated plain-English read of lobbying spend for REGN. Updated daily.
Moderate lobbying, rising
highModerate spend trending upward. Worth monitoring: a sustained rise from this base could reach the heavy tier within a year if the trajectory holds.
What will probably happen
- A rising trend without an obvious single catalyst suggests broadening DC engagement: a structural shift, not a one-quarter reaction.
- Spend is spread across many issue areas: the company has diverse regulatory exposure and is fighting on multiple fronts simultaneously.
What to do
- If you HOLD this stock
- This lobbying read is structural, not a timing signal. Hold as planned; revisit if trajectory changes next quarter.
- If you're EVALUATING this stock
- No sharp lobbying signal to factor into entry timing. Evaluate on fundamentals.
- If you trade OPTIONS
- No clean options signal derived from this lobbying read.
21 quarters of history with $12.92M in total spend: sufficient data for a reliable trajectory read.
Technical details
Technical analysis
- Spend tier
- Moderate
- Trajectory
- Rising
- Issue concentration
- Broad
- Registrant base
- In house
- Last quarter
- $860.0K
- Last 4Q total
- $3.57M
- Prior 4Q total
- $2.78M
- Quarters on record
- 21
- Unique issue areas
- 7
- Unique registrants
- 9
- Top issue area
- COPYRIGHT/PATENT/TRADEMARK (37% of spend)
- Top registrant
- REGENERON PHARMACEUTICALS, INC (73% of spend)
Key levels
| Level | Value |
|---|---|
| last quarter amount | 860,000 |
| last 4q total | 3,570,000 |
| prior 4q total | 2,780,000 |
| total amount | 12,920,000 |
| top issue pct | 0.374 |
| top registrant pct | 0.729 |
Caveats
- Lobbying disclosures are quarterly and reflect activity already past. The signal is structural, not timing.
- The primary registrant appears to be an in-house government-affairs operation. In-house lobbying may not be captured in full by third-party disclosure data.